Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/clients/e018409a36d8d382bd5c9d12746db954/sites/oncodesign-joomla.propulse.dev/plugins/system/helix3/core/classes/menu.php on line 89

Scientific Advisory Board

Oncodesign company

Ed Roberts, PhD

Ed Roberts, PhD, is a medicinal chemist with over 30 years’ experience in both industrial and academic R&D on new drugs covering numerous therapeutic areas.

He has held executive positions at Parke-Davis, AstraZeneca and Roche, where he was senior vice-president of all discovery chemistry at the Basel Headquarters. He has been involved in the development of several molecules that successfully completed their clinical stage development and market launch. His latest developments are currently in preclinical development for migraine, in phase III for Crohn's disease and Ulcerative colitis, and awaiting NDA approval from the FDA for multiple sclerosis.

Ed Roberts currently holds the position of Professor, Department of chemistry at the Scripps Research Institute, La Jolla, California, in the department of molecular medicine. He is the co-founder of BlackThorn therapeutics.


Sergio Roman-Roman, PharmD, PhD

Sergio Roman-Roman, PharmD, PhD, is the Director of the SIRIC (French label of Comprehensive Cancer Center) of Institut Curie in Paris. He was before the Director of translational research, where he coordinated the preclinical oncology programs and headed a group of scientists and physicians involved in research on uveal melanoma.

Before that, he held various scientific positions at Institut Gustave Roussy, Roussel-Uclaf, Aventis, and Proskelia Pharmaceuticals. He is the author or co-author of over 60 peer-reviewed scientific articles.


Michel Janicot, PhD

Michel Janicot holds a PhD in biochemistry from the Paris VII University.

He has been involved for over 20 years in multiple pharmaceutical laboratories, such as Janssen (Johnson & Johnson) and Sanofi, where he led international multidisciplinary teams working on the preclinical and clinical development of small molecules or biologics to treat cancer. Since May 2012, he has had his own consultancy firm serving international biotechnology companies, government agencies and investors to develop R&D projects in oncology, inflammation, immunology, ophthalmology and fibrosis.


Jean-Yves Bonnefoy, PhD

Jean-Yves Bonnefoy, PhD, is an immunologist. He held management positions for over 20 years at GSK, Pierre Fabre and then Transgene. He also initiated and ran the cancer centre of excellence Cancéropôle Lyon Rhône-Alpes from 2002 to 2005.

Jean-Yves Bonnefoy is currently President & CEO of Anagenesis Biotechnologies and Alms Therapeutics,  member of the investment committee of the TTO Conectus Alsace and of the steering committee of Matwin, member of the scientific advisory boards of iTeos Therapeutics, Amal Therapeutics, and President of Syndivia. He is the author or co-author of over 230 peer-reviewed scientific articles and reviews.

Pr Pierre Fumoleau

Professor Pierre Fumoleau is a world-renowned oncologist.

Before holding the position of director General Manager of the Georges-François Leclerc cancer centre in Dijon, he was in charge of translational and medical oncology research units at the Centre Georges-François Leclerc and the Centre René Gauducheau in Nantes. Since From 1996 to 2000, he has been acting acted as president of the early clinical trials group of the European Organisation for Research and Treatment of Cancer (EORTC).

He had led major clinical trials on most of the new cancer therapies discovered in the past 30 years.

Mats Bergström

Mats Bergström holds a degree in mathematics, physics and medical physics. He participated in the development of one of the first PET cameras at the Karolinska Institute in Stockholm.

He was also appointed director of the preclinical laboratory at the Uppsala PET centre in Sweden, director of the PET program at Novartis, then director of biology and imaging expert at GSK, before joining Roche as senior expert in imaging sciences.

Mats Bergström is world-renowned expert on PET tracer research. He initiated over 80 clinical trials on new PET tracers.